Mohammad Nour Zabad

Mohammad Nour Zabad practices at SSM Cancer Care South Schc - HOPD in Fenton, Missouri.

Mohammad Nour Zabad's NPI, 1609109883, was assigned on September 6, 2009. Mohammad Nour Zabad holds Missouri license 2019009597.

Mohammad Nour Zabad's primary practice is SSM Cancer Care South Schc - HOPD, at 1011 Bowles Ave, Fenton, MO 63026.

Mohammad Nour Zabad's primary practice is SSM Cancer Care South Schc - HOPD in Fenton, Missouri. Mohammad Nour Zabad is also affiliated with SSM Health St. Clare Hospital - Fenton. The medical group on file is SSM Health Medical Group. Dmand AI also links Mohammad Nour Zabad to 4 more hospitals, 3 group practices and clinics and 2 medical groups, each named with a free account. Mohammad Nour Zabad's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Mohammad Nour Zabad practices, 9 sites in all. Vendor and product names are available with a free account.

Cardiovascular disease is Mohammad Nour Zabad's primary specialty in the NPI Registry, under taxonomy code 207RC0000X. Dmand AI has Mohammad Nour Zabad's licenses on file in 2 states: Missouri and New York.

CMS data shows 1,332 Medicare services from Mohammad Nour Zabad across 15 procedure codes in 2024, for 763 Medicare patients. Medicare paid $57,016 for them.

CMS counts 763 Medicare patients who saw Mohammad Nour Zabad in 2024. The largest group is 65 to 74, with 304 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 25% are also on Medicaid. Their average risk score is 2.34, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Mohammad Nour Zabad's median patient age at 72, with 53% women.

In 2024, Mohammad Nour Zabad wrote 1,868 Medicare Part D claims for 459 patients. 81% of them were for generic drugs. CMS names the drug for 1,672 of them, across 25 drugs with 11 or more claims each, at $300,292 in total drug cost. In 2023, CMS named 827 claims across 21 drugs.

Mohammad Nour Zabad accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 183 general payments to Mohammad Nour Zabad from 23 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 86% of the total. Astellas Pharma US Inc paid the most, $413.